Completed NA INTERVENTIONAL 2-arm NCT01769560

MeFirst: A Tailored Intervention to HPV Vaccine Decision Making

Sponsor: University of Michigan

Conditions Human Papillomavirus-Related Carcinoma

Interventions MeFirst Tailored Intervention

Updated 5 times since 2017 Last updated: Jul 21, 2015 Started: Jan 31, 2013 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Human Papillomavirus-Related Carcinoma, this trial is completed. The trial is conducted by University of Michigan and has accumulated 5 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Michigan

Data source: University of Michigan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States